Acute Hepatic Porphyria (AHP) Treatments
Find Acute Hepatic Porphyria (AHP) Treatments
Brand Name
Givlaari
Generic Name
Givosiran
View Brand Information FDA approval date: December 12, 2019
Classification: Small Interfering RNA
Form: Injection
What is Givlaari (Givosiran)?
GIVLAARI is indicated for the treatment of adults with acute hepatic porphyria . GIVLAARI is an aminolevulinate synthase 1-directed small interfering RNA indicated for the treatment of adults with acute hepatic porphyria .
Approved To Treat
Save this treatment for later
Not sure about your diagnosis?
Tired of the same old research?
Related Clinical Trials
ELEVATE, a Global Observational Longitudinal Prospective Registry of Patients With Acute Hepatic Porphyria (AHP)
Summary: This global patient registry is being conducted to characterize the natural history and real-world clinical management of patients with AHP, and to further characterize the real-world safety and effectiveness of givosiran and other approved AHP therapies.